Bayer: new approval for protate cancer in China

(CercleFinance.com) - Bayer has announced that the Chinese National Medical Products Authority (NMPA) has approved Nubeqa (darolutamide), in combination with docetaxel, for the treatment of patients with hormone-sensitive metastatic prostate cancer (mHSPC).


Nubeqa was already approved in China for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) at high risk of developing metastatic disease.


Copyright (c) 2023 CercleFinance.com. All rights reserved.